Department of the Army April 16, 2008 – Federal Register Recent Federal Regulation Documents

In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), announcement is made of the intent to grant an exclusive, royalty- bearing, revocable license to U.S. Patent 6,825,323, filed January 10, 2001, entitled ``Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using the same'' and foreign rights (PCT/US01/000725) to ProFibrix B.V., with its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands.